Pharma BD Deal Intelligence
A $1.2B glucose-monitoring bolt-on that misfired on its first act—Abbott's discontinued FreeStyle Navigator CGM—before the same Alameda team it acquired delivered FreeStyle Libre, now a $6.8B/year franchise. A slow-burn win, not a clean one.
A $1.2B glucose-monitoring bolt-on that, through a discontinued first-gen CGM and a two-decade R&D detour at the same Alameda site, became the foundation of Abbott's $6.8B/year FreeStyle Libre franchise — one of medtech's great long-tail payoffs, though not a clean or fast one.
Full analysis, sources & comparables →Abbott agrees to acquire TheraSense, taking advantage of a growing US diabetes market; deal expected to close Q2 2004.
FreeStyle Libre, the long-tail product of Abbott's TheraSense buy, has become Abbott's flagship diabetes franchise but now faces rising CGM competition from…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Diabetes blood glucose monitoring; $27/share cash; merged into Abbott Diabetes Care; closed Q2 2004
A $1.2B glucose-monitoring bolt-on that, through a discontinued first-gen CGM and a two-decade R&D detour at the same Alameda site, became the foundation of Abbott's $6.8B/year FreeStyle Libre franchise — one of medtech's great long-tail payoffs, though not a clean or fast one.
Assessment window: 15yr post-close.
1.5M US cases/yr
Diabetes mellitus, predominantly type 2, requires daily blood glucose monitoring to titrate insulin and oral therapy and prevent micro/macrovascular complications. In 2004, fingerstick self-monitoring devices were the standard of care; continuous glucose monitoring was nascent. CDC currently estimates 40.1M Americans live with diabetes and ~1.5M are newly diagnosed annually.
The 2004 US blood glucose monitoring market was a four-firm oligopoly: Roche Diagnostics (Accu-Chek), Johnson & Johnson's LifeScan (OneTouch), Bayer (Ascensia), and Abbott via its 1996 MediSense acquisition. TheraSense had launched FreeStyle in June 2000 and rapidly took share with the smallest sample size in the category (0.3 µL vs ~1 µL competitors), enabling alternate-site testing on the forearm. The pipeline FreeStyle Navigator was a continuous glucose monitor pending FDA clearance, and the CozMore system (with Deltec) integrated testing with insulin delivery. Abbott's $1.2B all-cash bid at $27/share consolidated MediSense + TheraSense into Abbott Diabetes Care, giving Abbott both a current-generation strip business and a CGM optionality play. The deal proved strategically vindicated: this same franchise eventually birthed the FreeStyle Libre flash glucose monitor (FDA 2017), which became one of the most successful medical devices ever and a multi-billion-dollar Abbott growth driver. At deal time, analysts viewed the price as full but justified given TheraSense's growth trajectory and Abbott's need to defend against Roche/J&J in a market projected to grow with global diabetes prevalence.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / TheraSense Inc. (this deal) | 2004 | $1.2B | 81 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
| Abbott Laboratories / Genentech, Inc. (Roche Group) | 2007 | — | 79 |
← Browse all deals · How we score deals
More: 2004 deals · Abbott Laboratories deals